贝伐珠单抗注射液 | China Drugs ListBevacizumab injection | China Drugs List
本页为公开参考信息，不构成医疗建议、处方或药品供应要约。请向持证专业人士确认当前批准情况、可获得性及适用性。
其他
- 商品名
- Avastin
- 企业
- Genentech, Inc. (美国产品); Roche Registration GmbH (欧盟上市许可持有人)Genentech, Inc. (US product); Roche Registration GmbH (EU authorization holder)
- 药品类型
- 生物药Biologic
- 治疗领域
- 肿瘤科Oncology
- 公开来源记录的适应症
- 美国来源摘要：部分用途包括与氟尿嘧啶类化疗联合治疗转移性结直肠癌；与卡铂/紫杉醇联合一线治疗不可切除、局部晚期、复发或转移性非鳞状非小细胞肺癌；成人复发性胶质母细胞瘤；与干扰素α联合治疗转移性肾癌；以及与化疗联合治疗特定宫颈癌和卵巢/输卵管/腹膜癌。与阿替利珠单抗联合，用于既往未接受全身治疗的不可切除或转移性肝细胞癌。方案、既往治疗和疾病分期限制因适应症不同；详见所链接的说明书。United States source summary: Selected uses include metastatic colorectal cancer with fluorouracil-based chemotherapy; first-line unresectable, locally advanced, recurrent or metastatic non-squamous non-small cell lung cancer with carboplatin/paclitaxel; recurrent adult glioblastoma; metastatic renal cancer with interferon alfa; and specified cervical and ovarian/fallopian-tube/peritoneal cancers with chemotherapy. With atezolizumab for unresectable or metastatic hepatocellular carcinoma without prior systemic therapy. Regimen, prior-treatment and disease-stage restrictions differ by indication; see the linked label.
- 适应症来源与口径
- 美国处方资料, 修订于 2022年9月； 查阅于 2026年11月2日. 部分境外适应症；不确立中国批准范围。US prescribing information, revised September 2022; accessed 2 November 2026.. Selected overseas indications; does not establish the Chinese approved scope.
- 说明书信息局限
- 已链接境外官方处方资料；尚未核实完整的现行中国说明书。Overseas official prescribing information linked; a complete current Chinese label has not been verified.
- 中国可获得性状态
- 本次英文来源核查未独立核实中国批准、现行批准适应症及持续在售情况。Chinese approval, current approved indications and continuous market availability have not been independently verified in this English-source review.
- 海外状态
- 请参阅所链接的境外监管机构或厂商证据。批准及适应症因司法辖区而异；尚未确认当前供应情况。See the linked overseas regulator / manufacturer evidence. Approval and indications are jurisdiction-specific; current supply is not established.
- 医保分类
- 尚未核实Not yet verified
- 医保版本
- 中国国家医保信息待核实Chinese national insurance review pending
- 医保核查说明
- 本次新增记录尚未确定报销资格；缺少信息不代表未被纳入。No reimbursement determination was made for this addition; missing information is not proof of exclusion.
来源
- https://www.gene.com/download/pdf/avastin_prescribing.pdf
- Avastin——美国官方产品资料Avastin — official United States product information
Official prescribing information · US prescribing information, revised September 2022; accessed 2 November 2026.
已打开完整官方PDF，并核对药品身份及相关适应症文字。此境外来源不确立中国批准范围。Full official PDF opened; medicine identity and relevant indication text checked. This overseas source does not establish the Chinese approved scope.
- Avastin——EMA评估和产品概述Avastin — EMA assessment and product overview
Regulatory product overview · Accessed 2 November 2026
英文监管资料；所列许可持有人对应欧盟产品，并非中国仿制药或生物类似药。English regulatory reference; authorization holder is identified for the EU product, not a Chinese generic or biosimilar.
- 得克萨斯州卫生服务部（DSHS）——2026年度WAC报告Texas DSHS — 2026 annual WAC report
Supplied report reference · Report dated 25 October 2026
保留原报告引用以便追溯。仅凭此引用不能核实中国批准、品牌身份、制剂等效性或同口径价格。WAC计价单位及包装换算须另行确认。Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
- FDA NDC目录——包装参考FDA NDC directory — packaging reference
Supplied report reference · Report dated 25 October 2026
保留原报告引用以便追溯。仅凭此引用不能核实中国批准、品牌身份、制剂等效性或同口径价格。WAC计价单位及包装换算须另行确认。Original report citation retained for traceability. This citation alone does not verify Chinese approval, brand identity, equivalent formulations or like-for-like prices. WAC unit and pack conversions require separate confirmation.
证据核查日期：